Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Portfolio Pulse from
Summit Therapeutics has partnered with Pfizer to explore the use of ivonescimab, a PD-1/VEGF bispecific antibody, in combination with Pfizer's ADCs for treating solid tumors.
February 25, 2025 | 1:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer collaborates with Summit Therapeutics to explore the use of its ADCs with ivonescimab, potentially expanding its oncology treatment options.
This partnership could expand Pfizer's oncology portfolio, enhancing its market position and potentially leading to positive investor sentiment.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70
POSITIVE IMPACT
Summit Therapeutics has entered a collaboration with Pfizer to evaluate ivonescimab with Pfizer's ADCs in solid tumors, potentially enhancing its cancer treatment portfolio.
The collaboration with Pfizer could significantly enhance Summit's product offerings and market position in cancer treatment, likely boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90